Blueprint Medicines Stock (NASDAQ: BPMC) stock price, news, charts, stock research, profile.
Open | $95.000 |
Close | $94.860 |
Volume / Avg. | 659.240K / 809.341K |
Day Range | 93.500 - 95.980 |
52 Wk Range | 41.540 - 101.000 |
Market Cap | $5.808B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 60 |
Short Interest | 11.31% |
Days to Cover | 6.86 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Blueprint Medicines (NASDAQ: BPMC) through any online brokerage.
Other companies in Blueprint Medicines’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Ionis Pharmaceuticals (NASDAQ:IONS) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Blueprint Medicines (NASDAQ: BPMC) was reported by Needham on Monday, February 26, 2024. The analyst firm set a price target for 97.00 expecting BPMC to rise to within 12 months (a possible 2.26% upside). 37 analyst firms have reported ratings in the last year.
The stock price for Blueprint Medicines (NASDAQ: BPMC) is $94.86 last updated March 28, 2024 at 4:01 PM EDT.
There are no upcoming dividends for Blueprint Medicines.
Blueprint Medicines’s Q4 earnings are confirmed for Wednesday, February 15, 2023.
There is no upcoming split for Blueprint Medicines.
Blueprint Medicines is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.